Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 




Global Oncology Young Investigator Award (GO YIA): Implementation Science to Address Oncology Care in LMICs 

The Conquer Cancer Global Oncology Young Investigator Award (GO YIA) provides research funding to early-career investigators to encourage and promote quality research in global oncology and to develop the next generation researchers to address global health needs.

The project needs to be a research exercise – identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and also researching the cost of creating sustainable models where they currently do not exist. The ideal grantee will have a mentor who is established, and will need to be within a team or be paired with a high-income institution working for a period of time in a lower resource setting. 

The Global Oncology YIA is intended to support: 

1. Research by investigators in low resource settings on scientific questions specific to those settings. This research has potential to offer “reverse innovation” insights that could influence practice in a wide range of practice settings. 

2. Research by investigators in high resource settings on issues in resource-limited settings. 

3. Collaborative research (high and low resource investigators) on questions of shared concern, such as studying a cancer type that affects a small population in the U.S. but is common in another country.

Application Deadline: June 27, 2019

Learn More>>


Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required) (RFA-CA-19-035)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes.

Application Deadline: June 28, 2019, by 5:00 PM local time of applicant organization. 

Learn More>>


Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional) (PAR-19-251)

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. 

Application Deadline: July 2, 2019

Learn More>>



Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional) (PAR-19-252) 

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

Application Deadline: July 2, 2019

Learn More>>




NCCN/AstraZeneca Quality of Care & Clinical Care Pathways in Unresectable Stage III / Stage IV Non-Small Cell Lung Cancer

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new opportunity to improve patient care and outcomes in advanced non-small cell lung cancer (NSCLC). The Request for Proposals (RFP) outlines the scope and process that will be followed for the submission of Letters of Intent (LOI).

The intent of this RFP is to encourage NCCN Member Institutions to submit LOIs describing concepts for developing, implementing, and evaluating healthcare provider performance and/or healthcare quality improvement initiatives to enhance patient care and outcomes in unresectable stage III NSCLC patients and stage IV NSCLC patients receiving first line therapy. 

Letter of Intent (LOI) Deadline: July 9, 2019, 11:59 PM ET
Susan G. Komen Career Catalyst Research Grant 

The topic area for the FY20 Career Catalyst Research Award is Redefining Metastatic Breast Cancer through Liquid Biopsy. The goal of this focus area is to support outstanding research seeking to use liquid biopsy techniques to improve treatment, detection, and understanding of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. Komen requests Letters of Intent for research projects that address one of the following focus areas: 
  • Refining treatment of metastatic breast cancer 
  • Early detection of metastatic breast cancer 
Applications that fit the focus areas as detailed in the LOI Announcement and include studies that address metastatic breast cancer disparities, or leverage data science to better understand and treat metastatic breast cancer are highly encouraged. The award provides funding up to $450,000 (direct and indirect costs combined) over 3 years. 

LOI Deadline: July 10, 2019; Application Deadline: September 25, 2019

To Apply>>
Learn More>>



Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional) (PAR-19-264) 
 
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype.

Application Deadline: July 10, 2019 by 5:00 PM 


Tobacco Regulatory Science (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Estimated Application Due Date: July 19, 2019
 



NCCN/AstraZeneca Quality of Care Evaluations in Advanced Ovarian Cancer

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for improving patient care and outcomes in Stage III, Stage IV and recurrent epithelial ovarian cancer (EOC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit letters of intent (LOIs) describing concepts for developing, implementing, and evaluating initiatives to improve patient outcomes in Stages III/IV and recurrent EOC. Studies aimed at enhancing the quality of multiple aspects of patient interaction and management throughout the clinical care continuum will be eligible. Special consideration will be given to “outside the box” innovative projects, with a special focus on optimizing testing and effectiveness of new healthcare-related paradigms.

Application Deadline: July 22, 2019, by 11:59 PM EST



Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019




Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care 

National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer Global Medical Grants (Pfizer) to offer a new grant opportunity for improving care for patients with metastatic breast cancer (MBC). The intent of this RFP is to encourage investigators at NCCN Member Institutions to submit proposals describing concepts for developing best practices and collaborative oncology care models between academic centers and referring community providers. The overarching goal is to leverage the expertise and resources of NCCN-designated cancer centers to improve quality and outcomes across the continuum of care for all MBC patients.

Proposal Deadline: 11:59 PM ET, August 28, 2019




Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.

Application Deadline: August 30, 2019, by 5:00 PM

Learn More>>

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Current opportunities are listed below. 

View a full list of grant opportunities available throughout the year>> 



Yale Spore in Skin Cancer Developmental Research Awards and Career Enhancement Awards 

DRA and CEA projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as R01 or equivalent grants. 

Developmental Research Program Awards will support a broad spectrum of innovative pilot projects applicable to human skin cancer risk, prevention, diagnosis, prognosis, or treatment. 
Career Enhancement Program Awards will support new investigative cutaneous oncologists and other scientists committed to multidisciplinary studies investigating the relevance of biological discoveries in human skin cancer risk, prevention, diagnosis, prognosis or treatment, and enhance the careers of individuals who are already productively investigating this field. 

DRP-eligible investigators include established and junior investigators (faculty appointment higher than Postdoctoral Fellow or Research Associate). They include faculty who currently lead skin cancer programs but wish to test an idea clearly distinct from current or pending grants or may lead programs not directed at skin cancer, but be interested in exploring the applicability of their expertise to skin cancer. 

CEP funds are often awarded to faculty within five years of appointment as Assistant Professor. Previous recipients of SPORE DRP and CEP funds are generally ineligible to be P.I.s of new projects within 3 years of completion of their previous funding. 

Application Deadline: July 1, 2019 by 5:00 p.m. 

Learn More>>



Luminary Award of Excellence

The YNHH Smilow Luminary Award of Excellence will serve to recognize, and ceremoniously acknowledge, those individuals and/or teams who consistently exceed performance expectations and deliver high quality cancer care for our patients, families and the health system through community service, optimization/ innovative solutions, patient experience, leadership and research initiatives. Nominations should be submitted directly to  Luminary@ynhh.org